DiaMedica Therapeutics (NASDAQ:DMAC) Announces Earnings Results, Meets Estimates

DiaMedica Therapeutics (NASDAQ:DMAC) announced its quarterly earnings results on Thursday. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.21), FiscalAI reports.

DiaMedica Therapeutics Stock Performance

Shares of NASDAQ DMAC traded down $0.33 during midday trading on Thursday, hitting $9.33. 187,770 shares of the company traded hands, compared to its average volume of 201,430. DiaMedica Therapeutics has a 12-month low of $5.24 and a 12-month high of $11.00. The firm has a market cap of $503.17 million, a P/E ratio of -12.96 and a beta of 0.95. The stock has a 50-day moving average price of $8.11 and a 200 day moving average price of $7.19.

Wall Street Analyst Weigh In

DMAC has been the subject of several research analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of DiaMedica Therapeutics in a report on Thursday, October 15th. HC Wainwright reissued a “buy” rating and set a $12.00 target price on shares of DiaMedica Therapeutics in a research note on Tuesday, August 11th. Finally, Wall Street Zen upgraded DiaMedica Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 24th. Three research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, DiaMedica Therapeutics currently has a consensus rating of “Moderate Buy” and an average price target of $12.00.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc. is a clinical-stage biopharmaceutical company developing treatments for serious diseases, with a focus on preeclampsia and neurological conditions. Its lead candidate, DM199 (rinvecalinase alfa), is a recombinant form of human tissue kallikrein-1, an enzyme involved in regulating blood flow. DiaMedica is investigating DM199 for acute ischemic stroke and preeclampsia; it remains an investigational drug and is not approved for commercial use. The company is headquartered in Minneapolis, Minnesota, and conducts clinical development of its therapies.